Deep eutectic ionic liquids for therapeutics
Transforming ionic liquids into healthcare solutions
Deep eutectic ionic liquids for therapeutics
Transforming ionic liquids into healthcare solutions
Who We Are
Our Advantage
Our Mission
CAGE Bio Inc., currently a resident company at Johnson & Johnson Innovation, JLABS @ MBC BioLabs, is a clinical-stage startup exploiting its proprietary deep eutectic ionic liquid platform to develop novel products for dermatology, inflammation, and immunology.
Our Mission
Our Advantage
Our Mission
We believe that systemic exposure to drugs should be an exception. Our mission is to develop highly
effective products for localized treatment thereby minimizing side effects from systemic exposure.
Our Advantage
Our Advantage
Our Advantage
Deep eutectic ionic liquids exhibit broad-spectrum antimicrobial action in addition to exceptional solvation and permeation enhancement. Deep eutectic ionic liquids have shown the ability to deliver proteins (eg insulin) and charged macromolecules (eg siRNA) across the stratum corneum.
LEADERSHIP
Nitin Joshi, CEO
Ravi Srinivasan, Chairman of Board
Samir Mitragotri, Co-Founder
20+ years in drug development through approvals in the US and EU. Held senior positions at Elan, Alkermes, ALZA (J&J). Co-Founder, Incline Therapeutics acquired by The Medicines Company.
Samir Mitragotri, Co-Founder
Ravi Srinivasan, Chairman of Board
Samir Mitragotri, Co-Founder
Professor, Bioengineering and Biologically Inspired Engineering, Harvard University.
Member of the U.S. National Academy of Engineering, National Institute of Medicine, National Academy of Inventors.
Ravi Srinivasan, Chairman of Board
Ravi Srinivasan, Chairman of Board
Ravi Srinivasan, Chairman of Board
Serial biotech entrepreneur, multiple startups and exits. StrataGent(acquired by Corium), StemPar, OncoNano(raised $100M), Symyx, ForSightV5 (acquired by Allergan for $90M).
Welcome! Check out our latest news.
Scientists from Harvard University and Mayo Clinic validate our ionic liquid platform for treating large hepatocellular tumors to help bridge more patients to liver transplantation.